ArticleBMC cancer2026

Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2).

Linde Kehmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.